Austėja Dapkutė1, Jurgita Vainauskienė2, Kristina Ryliškienė3,2. 1. Centre of Neurology, Vilnius University, Santariskiu st. 2, 08661, Vilnius, Lithuania. austeja.dapkute@mf.stud.vu.lt. 2. Centre of Neurology, Kardiolitos klinikos, Laisves pr. 64A, 05263, Vilnius, Lithuania. 3. Centre of Neurology, Vilnius University, Santariskiu st. 2, 08661, Vilnius, Lithuania.
Abstract
BACKGROUND: Despite development of new therapies, migraine remains an undertreated illness. It is important to understand patients' preferences and perceptions of using a certain therapy. We present data from a nationwide Lithuanian survey of patients' experience using erenumab for the treatment of high frequency episodic and chronic migraine. METHODS: An anonymous internet survey was distributed on February-March 2021 to the members of Migraine Association of Lithuania. All adult respondents who reported using at least one dose of erenumab were included in the study. RESULTS: Out of 145 respondents, 75.2% had chronic migraine, and 31.7% had medication overuse headache. Patients received an average of 6 (IQR 4-9) erenumab doses. 93.1% respondents found erenumab effective, and 72.6% experienced improvement during the first month. MHDs were reduced by 9.8 (SD 6.0) (P < 0.001), and MMDs by 7.2 (SD 5.2) days (P < 0.001). 78.6% respondents achieved ≥ 50% reduction and 47.6% achieved ≥ 75% reduction of MMDs. 13.8% patients indicated a wearing-off effect during the treatment course, and 37.8% - some wearing-off between injections. Constipation was the most frequent adverse event (32.6%). 47.2% of patients who had a positive erenumab effect and discontinued treatment experienced migraine rebound in 6 (SD 2.0) weeks. CONCLUSION: Erenumab is perceived as an effective and safe treatment. Further studies are needed to investigate a post-cessation deterioration of achieved improvement. HIGHLIGHTS: • Vast majority of patients experience stable or increasing effect of erenumab. • Erenumab efficacy usually becomes evident during the first month of treatment. • Erenumab is perceived significantly better than non-specific preventive medications. • Almost 40% of patients experienced some wearing-off between injections. • Almost half of patients experience migraine rebounds after treatment cessation.
BACKGROUND: Despite development of new therapies, migraine remains an undertreated illness. It is important to understand patients' preferences and perceptions of using a certain therapy. We present data from a nationwide Lithuanian survey of patients' experience using erenumab for the treatment of high frequency episodic and chronic migraine. METHODS: An anonymous internet survey was distributed on February-March 2021 to the members of Migraine Association of Lithuania. All adult respondents who reported using at least one dose of erenumab were included in the study. RESULTS: Out of 145 respondents, 75.2% had chronic migraine, and 31.7% had medication overuse headache. Patients received an average of 6 (IQR 4-9) erenumab doses. 93.1% respondents found erenumab effective, and 72.6% experienced improvement during the first month. MHDs were reduced by 9.8 (SD 6.0) (P < 0.001), and MMDs by 7.2 (SD 5.2) days (P < 0.001). 78.6% respondents achieved ≥ 50% reduction and 47.6% achieved ≥ 75% reduction of MMDs. 13.8% patients indicated a wearing-off effect during the treatment course, and 37.8% - some wearing-off between injections. Constipation was the most frequent adverse event (32.6%). 47.2% of patients who had a positive erenumab effect and discontinued treatment experienced migraine rebound in 6 (SD 2.0) weeks. CONCLUSION: Erenumab is perceived as an effective and safe treatment. Further studies are needed to investigate a post-cessation deterioration of achieved improvement. HIGHLIGHTS: • Vast majority of patients experience stable or increasing effect of erenumab. • Erenumab efficacy usually becomes evident during the first month of treatment. • Erenumab is perceived significantly better than non-specific preventive medications. • Almost 40% of patients experienced some wearing-off between injections. • Almost half of patients experience migraine rebounds after treatment cessation.
Authors: Andrew M Blumenfeld; Lisa M Bloudek; Werner J Becker; Dawn C Buse; Sepideh F Varon; Gregory A Maglinte; Teresa K Wilcox; Ariane K Kawata; Richard B Lipton Journal: Headache Date: 2013-03-04 Impact factor: 5.887
Authors: Marcelo E Bigal; Michel Ferrari; Stephen D Silberstein; Richard B Lipton; Peter J Goadsby Journal: Headache Date: 2009-02 Impact factor: 5.887
Authors: Zsolt Hepp; David W Dodick; Sepideh F Varon; Jenny Chia; Nitya Matthew; Patrick Gillard; Ryan N Hansen; Emily Beth Devine Journal: Cephalalgia Date: 2016-11-12 Impact factor: 6.292